Last Price$0.90NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/12/22

Today's Change0(0.00%)
Bid (Size)$0.85 (20)
Ask (Size)$0.94 (26)
Day Low / HighN/A - N/A
Volume127.5 K

View Biotechnology IndustryPeer Comparison as of 08/12/2022


Aravive Inc ( NASDAQ )

Price: $0.90
Change: -0.03 (3.22%)
Volume: 127.5 K
4:00PM ET 8/12/2022

BioCardia Inc ( NASDAQ )

Price: $1.57
Change: -0.01 (0.63%)
Volume: 38.9 K
3:59PM ET 8/12/2022

Onconova Therapeutics Inc ( NASDAQ )

Price: $1.34
Change: +0.02 (1.70%)
Volume: 100.9 K
3:59PM ET 8/12/2022

Eloxx Pharmaceuticals Inc ( NASDAQ )

Price: $0.33
Change: +0.05 (18.40%)
Volume: 525.4 K
3:56PM ET 8/12/2022

Cell Source Inc ( OTC )

Price: $0.75
Change: 0.00 (0.00%)
Volume: 12.3 K
1:48PM ET 7/19/2022

Read more news Recent News

-- Earnings Flash (ARAV) ARAVIVE Posts Q2 Revenue $1.6M
7:01AM ET 8/11/2022 MT Newswires


Roth Capital Initiates Aravive at Buy with $15 Price Target
10:35AM ET 6/03/2022 MT Newswires

Aravive (ARAV) has an average rating of buy and price targets ranging from $6 to $26, according to analysts polled by Capital IQ. (MT Newswires covers...

Aravive Appoints Rudy Howard as CFO
7:13AM ET 6/03/2022 MT Newswires

Aravive (ARAV) said Friday that it has appointed Rudy Howard as chief financial officer, effective immediately. Vinay Shah has stepped down as CFO for...

Piper Sandler Adjusts Aravive's Price Target to $6 From $9, Reiterates Overweight Rating
5:10AM ET 5/13/2022 MT Newswires

Aravive (ARAV) has an average rating of buy and price targets ranging from $6 to $26, according to analysts polled by Capital IQ. (MT Newswires covers...

View all Commentary and Analysis

Aravive (ARAV) Investor presentations - Slideshow
11:53AM ET 5/25/2022 Seeking Alpha

Company Profile

Business DescriptionAravive, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX. View company web site for more details
AddressRiver Oaks Tower
Houston, Texas 77098
Number of Employees14
President, Chief Executive Officer & DirectorGail Frances McIntyre
Chief Operating OfficerLeonard Scott Dove
Chief Financial & Accounting OfficerRudy C. Howard
Chief Medical OfficerRobert B. Geller

Company Highlights

Price Open$0.95
Previous Close$0.93
52 Week Range$0.80 - 4.40
Market Capitalization$27.3 M
Shares Outstanding30.5 M
SectorHealth Technology
Next Earnings Announcement10/27/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.42
Beta vs. S&P 500N/A
Revenue$1.4 M
Net Profit Margin-910.48%
Return on Equity-134.06%

Analyst Ratings as of 06/02/2022

Consensus RecommendationConsensus Icon
Powered by Factset